疾病修饰治疗对镰状细胞贫血患儿三尖瓣反流速度的纵向影响
这项前瞻性单中心研究纳入204例HbSS或HbSβ0地中海贫血患儿,评估疾病修饰治疗对三尖瓣反流速度(TRV)的影响。结果显示血红蛋白每升高1.0 g/dL与TRV降低0.03 m/s相关,羟基脲暴露与2年后平均TRV下降5%相关,提示羟基脲可能减轻TRV升高。
要点
- 羟基脲暴露与2年时平均TRV下降5%相关。
核心结论
- 羟基脲治疗可能减轻镰状细胞贫血患儿的TRV升高,可能源于溶血减少和贫血改善。
研究设计与样本
- 前瞻性单中心研究,纳入204例HbSS或HbSβ0地中海贫血患儿,平均年龄10.6岁(范围5-18岁),基线及2年后重复超声心动图评估TRV。
主要发现
- 与基线相比,羟基脲暴露(持续或新开始)与2年评估时平均TRV下降5%相关。
临床怎么用
- 对于镰状细胞贫血患儿,羟基脲治疗可能有助于降低TRV,可考虑作为疾病修饰治疗以改善贫血和溶血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Elevated tricuspid regurgitant velocity (TRV) ≥2.5 m/s is a predictor of disease severity in adults and children with sickle cell anemia (SCA), but how disease-modifying therapies (DMTs) affect this biomarker is incompletely understood. We investigated the effect of DMTs on TRV elevation in children. In a prospective single-center study, 204 subjects with HbSS or HbSβ0 thalassemia (mean age, 10.6 years; range, 5-18) had echocardiograms with assessment of TRV, with repeat evaluations after 2 years of observation. One-hundred and twelve participants received DMTs (hydroxyurea, n = 72; monthly erythrocyte transfusions, n = 40), 58 did not receive any DMT, and 34 were begun on hydroxyurea during this observation period. In the entire cohort, an increase in hemoglobin of 1.0 g/dL was associated with a 0.03-m/s decrease in TRV (P = .024), and a decrease in absolute reticulocyte count of 1.0 × 106/mL was associated with a 0.34-m/s decrease in TRV (P = .034). Compared with baseline, hydroxyurea exposure (continuous or newly started) was associated with an average 5% decline in mean TRV at the 2-year evaluation. Among participants newly started on hydroxyurea (mean treatment duration 1.2 ± 0.6 years), an increase in hemoglobin of 1.0 g/dL was associated with a 0.06-m/s decrease in TRV (P = .05). We conclude that hydroxyurea therapy may mitigate TRV elevation in children with SCA, possibly as a result of a reduction in hemolysis and improvement in anemia.
引用
- Rai P, Joshi VM, Goldberg JF, et al. Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia. Blood Adv. 2021. PMID: 33570630. doi:10.1182/bloodadvances.2020003197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。